Akesobio

Founded in 2012, Akeso, Inc. (“Akeso”) (9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of new innovative antibody drugs that are affordable to patients worldwide. The founder, Dr. Yu Michelle Xia, has over 26 years of experience in the pharmaceutical industry and academic research. Since its inception, Akeso has had the foresight to develop built a comprehensive in-house platform, covering target validation, antibody drug discovery and development, process development, and GMP-compliant commercial-scale manufacturing. The company has also successfully established a bi-specific antibody drug development technology platform (“Tetrabogy”). Akeso currently has a pipeline of over 20 innovative investigative drugs for the treatment of major diseases including cancer and autoimmune diseases, 12 (including 3 out-licensed) of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF).